These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1106 related articles for article (PubMed ID: 31769875)
1. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875 [TBL] [Abstract][Full Text] [Related]
2. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. John T; Akamatsu H; Delmonte A; Su WC; Lee JS; Chang GC; Huang X; Jenkins S; Wu YL Lung Cancer; 2018 Dec; 126():133-138. PubMed ID: 30527177 [TBL] [Abstract][Full Text] [Related]
3. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Papadimitrakopoulou VA; Mok TS; Han JY; Ahn MJ; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y; Akamatsu H; Theelen WSME; Su WC; John T; Sebastian M; Mann H; Miranda M; Laus G; Rukazenkov Y; Wu YL Ann Oncol; 2020 Nov; 31(11):1536-1544. PubMed ID: 32861806 [TBL] [Abstract][Full Text] [Related]
4. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259 [TBL] [Abstract][Full Text] [Related]
5. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198 [TBL] [Abstract][Full Text] [Related]
6. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281 [TBL] [Abstract][Full Text] [Related]
7. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876 [TBL] [Abstract][Full Text] [Related]
8. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). Wu YL; Ahn MJ; Garassino MC; Han JY; Katakami N; Kim HR; Hodge R; Kaur P; Brown AP; Ghiorghiu D; Papadimitrakopoulou VA; Mok TSK J Clin Oncol; 2018 Sep; 36(26):2702-2709. PubMed ID: 30059262 [TBL] [Abstract][Full Text] [Related]
9. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors. Li C; Jia R; Liu H; Zhang B; Wang C Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780 [TBL] [Abstract][Full Text] [Related]
10. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study. Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929 [TBL] [Abstract][Full Text] [Related]
11. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Felip E; Cho BC; Gutiérrez V; Alip A; Besse B; Lu S; Spira AI; Girard N; Califano R; Gadgeel SM; Yang JC; Yamamoto S; Azuma K; Kim YJ; Lee KH; Danchaivijitr P; Ferreira CG; Cheng Y; Sendur MAN; Chang GC; Wang CC; Prabhash K; Shinno Y; Stroyakovskiy D; Paz-Ares L; Rodriguez-Cid JR; Martin C; Campelo MRG; Hayashi H; Nguyen D; Tomasini P; Gottfried M; Dooms C; Passaro A; Schuler M; Gelatti ACZ; Owen S; Perdrizet K; Ou SI; Curtin JC; Zhang J; Gormley M; Sun T; Panchal A; Ennis M; Fennema E; Daksh M; Sethi S; Bauml JM; Lee SH Ann Oncol; 2024 Sep; 35(9):805-816. PubMed ID: 38942080 [TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer. Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341 [TBL] [Abstract][Full Text] [Related]
13. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. Mok TS; Wu Y-L; Ahn M-J; Garassino MC; Kim HR; Ramalingam SS; Shepherd FA; He Y; Akamatsu H; Theelen WS; Lee CK; Sebastian M; Templeton A; Mann H; Marotti M; Ghiorghiu S; Papadimitrakopoulou VA; N Engl J Med; 2017 Feb; 376(7):629-640. PubMed ID: 27959700 [TBL] [Abstract][Full Text] [Related]
14. Detection of EGFR T790M mutation using liquid biopsy for non-small cell lung cancer: Utility of droplet digital polymerase chain reaction vs. cobas real-time polymerase chain reaction. Zungsontiporn N; Ouwongprayoon P; Boonsirikamchai P; Leelayuwatanakul N; Vinayanuwattikun C; Moonai K; Khongkhaduead E; Thorner PS; Shuangshoti S; Teerapakpinyo C Pathol Res Pract; 2024 Mar; 255():155213. PubMed ID: 38394807 [TBL] [Abstract][Full Text] [Related]
15. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328 [TBL] [Abstract][Full Text] [Related]
16. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial). Usui K; Yokoyama T; Naka G; Ishida H; Kishi K; Uemura K; Ohashi Y; Kunitoh H Jpn J Clin Oncol; 2019 Jun; 49(6):554-558. PubMed ID: 30809659 [TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). Asahina H; Tanaka K; Morita S; Maemondo M; Seike M; Okamoto I; Oizumi S; Kagamu H; Takahashi K; Kikuchi T; Isobe T; Sugio K; Kobayashi K Clin Lung Cancer; 2021 Mar; 22(2):147-151. PubMed ID: 33199228 [TBL] [Abstract][Full Text] [Related]
18. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260 [TBL] [Abstract][Full Text] [Related]
19. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382 [TBL] [Abstract][Full Text] [Related]
20. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]